Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Foghorn Therapeutics
Biotech
Merck discontinues development of 2 late-stage cancer assets
Merck is ending development of anti-TIGIT antibody vibostolimab and anti-LAG-3 antibody favezelimab, both of which are in phase 3 development.
Gabrielle Masson
Dec 16, 2024 5:39pm
Foghorn drops sole wholly owned clinical asset after AML failure
Dec 16, 2024 7:48am
BMS vet answers Foghorn’s call for CBO—Chutes & Ladders
Sep 6, 2024 8:30am
Mirati CEO exits—Chutes & Ladders
Aug 11, 2023 9:30am
Foghorn sinks eye tumor plans after glimpsing phase 1 data
Jun 28, 2023 8:45am
Foghorn has route back to clinic after FDA lifts yearlong hold
Jun 5, 2023 9:20am
